Gossamer Bio Receives 'Hold' Rating from Analysts

NodeGuardian

2026-03-29 10:59:23

Abstract generation in progress

Gossamer Bio, a clinical-stage biotech company, has received a consensus “Hold” rating from analysts, with a mixed outlook on its stock. The average 12-month price target is $5.43, and reviews include ‘Sell’, ‘Hold’, and ‘Buy’ recommendations, impacting investor sentiment and the company’s ability to fund drug development. This mixed view reflects the challenges Gossamer Bio faces in advancing its drug candidates through clinical trials and regulatory approvals.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes